ASIA PACIFIC HYPERPHOSPHATEMIA DRUG MARKET FORECAST 2019-2027

  • You are here:
  • Home
  • Reports
  • ASIA PACIFIC HYPERPHOSPHATEMIA DRUG MARKET FORECAST 2019-2027

ASIA PACIFIC HYPERPHOSPHATEMIA DRUG MARKET FORECAST 2019-2027

 The Asia-Pacific hyperphosphatemia drugs market is anticipated to grow at a faster CAGR of 17.37% during the forecast period of 2019-2027. The market worth is estimated to grow from $xx million in 2018 to $ xx million by 2027. The countries analyzed in the region include India, China, Japan, Australia and The Rest of Asia-Pacific.

ASIA PACIFIC HYPERPHOSPHATEMIA DRUG MARKET FORECAST 2019-2027

Asia Pacific Hyperphosphatemia Drugs Market by Formulation (Calcium-based Phosphate Binders, Aluminum-based Phosphate Binders, Magnesium-based Phosphate Binders, Iron-based Phosphate Binders) & by Geography

Request free sample

The Asia-Pacific hyperphosphatemia drugs market is anticipated to grow at a faster CAGR of 17.37% during the forecast period of 2019-2027. The market worth is estimated to grow from $xx million in 2018 to $ xx million by 2027.

The countries analyzed in the region include India, China, Japan, Australia and The Rest of Asia-Pacific. The Indian hyperphosphatemia drugs market is currently growing at the highest CAGR of xx% and is expected to lead the overall market growth in this region. India’s geriatric population is estimated to augment significantly over the next four decades. This increasing ageing population in India is the major driving factor for strengthening the demand of the hyperphosphatemia drugs market.

Major players for the Asia-Pacific hyperphosphatemia drugs market are Cipla, Amag Pharmaceuticals, DSM Biotech Pharmacal Keryx Biopharmaceuticals, Sun Pharm Inc., Ultragenyx,  Fermenta Biotech Ltd, Pfizer Inc., Roche Diagnostics Corporation, R.H. Moor Drug Co, Bruno Pharmaceutical Spa Sanofi, Shire, Fresenius Medical Care, Zeria Pharmaceutical and Vifor Pharma.

 

To request a free sample copy of this report, please complete the form below:

We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.

  1. RESEARCH SCOPE
    • STUDY GOALS
    • SCOPE OF THE MARKET STUDY
    • WHO WILL FIND THIS REPORT USEFUL?
    • STUDY AND FORECASTING YEARS
  2. RESEARCH METHODOLOGY
    • SOURCES OF DATA
      • SECONDARY DATA
      • PRIMARY DATA
    • TOP DOWN APPROACH
    • BOTTOM-UP APPROACH
    • DATA TRIANGULATION
    • ESTIMATION METHODOLOGY
  3. EXECUTIVE SUMMARY
    • MARKET SUMMARY
    • KEY FINDINGS
      • IRON-BASED HYPERPHOSPHATEMIA DRUGS IS A GAME CHANGER
  1. MARKET DETERMINANTS
    • MARKET SCOPE & DEFINITION
    • DRIVERS
      • GROWING PREVALENCE OF CHRONIC DISEASES
      • UNMET MEDICAL NEEDS
      • SKEWED POPULATION MIX TOWARDS ELDERLY PEOPLE
      • RISE IN PUBLIC AWARENESS
    • RESTRAINTS
      • LIMITATIONS LEVIED BY THE FOOD AND DRUG ADMINISTRATION (FDA)
      • GROWING SIDE EFFECTS OF THE HYPERPHOSPHATEMIA DRUGS
    • CHALLENGES
      • NON-ADHERENCE TO TREATMENT REGIMENS
      • SIDE EFFECTS OF DRUGS
      • LIMITED AVAILABILITY OF DRUGS
      • USE OF ADVANCED DIALYSIS TECHNIQUES
    • MARKET BY DOSAGE
      • SOLID
        • TABLET
        • POWDER
      • LIQUID
        • SOLUTION
  1. MARKET BY FORMULATION
    • CALCIUM-BASED PHOSPHATE BINDERS
    • ALUMINUM-BASED PHOSPHATE BINDERS
    • MAGNESIUM-BASED PHOSPHATE BINDERS
    • IRON-BASED PHOSPHATE BINDERS
    • OTHER PHOSPHATE BINDERS
  2. KEY ANALYTICS
    • PORTER’S FIVE FORCE MODEL
      • THREAT OF NEW ENTRANTS
      • BARGAINING POWER OF BUYERS
      • BARGAINING POWER OF SUPPLIERS
      • THREAT OF SUBSTITUTE PRODUCT
      • INTENSITY OF COMPETITIVE RIVALRY
    • OPPORTUNITY MATRIX
    • KEY BUYING CRITERIA
      • APPLICATION
      • PRICING
      • EFFECTIVENESS
      • AVAILABILITY
    • STRATEGIC RECOMMENDATION & STRATEGIC CONCLUSIONS
    • MARKET TRENDS
      • PATIENT ASSISTANCE PROGRAMS
      • STRATEGIC ALLIANCES
      • INCREASE IN R&D
    • PHOSPHATE BINDERS USAGES GUIDELINES
  3. GEOGRAPHIC ANALYSIS
    • ASIA PACIFIC
      • INDIA
      • CHINA
      • JAPAN
      • AUSTRALIA
      • SOUTH KOREA
      • REST OF APAC
  1. COMPETITIVE LANDSCAPE
    • MARKET SHARE ANALYSIS
    • COMPANY PROFILES
      • AMAG PHARMACEUTICALS
        • OVERVIEW
        • PRODUCT PORTFOLIO
        • SCOT ANALYSIS
        • STRATEGIC INITIATIVES
      • BIOTECH PHARMACAL
        • OVERVIEW
        • PRODUCTS PORTFOLIO
        • SCOT ANALYSIS
        • STRATEGIC INITIATIVES
      • BRUNO FARMACEUTICI SPA
        • OVERVIEW
        • PRODUCT PORTFOLIO
        • SCOT ANALYSIS
        • STRATEGIC INITIATIVES
      • CIPLA
        • OVERVIEW
        • PRODUCT PORTFOLIO
        • SCOT ANALYSIS
        • STRATEGIC INITIATIVES
      • FERMENTA BIOTECH LTD
        • OVERVIEW
        • PRODUCT PORTFOLIO
        • SCOT ANALYSIS
        • STRATEGIC INITIATIVES
      • FRESENIUS MEDICAL CARE
        • OVERVIEW
        • PRODUCT PORTFOLIO
        • SCOT ANALYSIS
        • STRATEGIC INITIATIVES
      • JOHNSON AND JOHNSON
        • COMPANY OVERVIEW
        • PRODUCT PORTFOLIO
        • SCOT ANALYSIS
        • STRATEGIC INITIATIVES
      • KERYX BIOPHARMACEUTICALS INC
        • OVERVIEW
        • SCOT ANALYSIS
        • STRATEGIC INITIATIVES
      • PFIZER INC.
        • OVERVIEW
        • PRODUCT PORTFOLIO
        • SCOT ANALYSIS
        • STRATEGIC INITIATIVES
      • ROCHE DIAGNOSTICS CORPORATION
        • OVERVIEW
        • PRODUCT PORTFOLIO
        • SCOT ANALYSIS
        • STRATEGIC INITIATIVES
      • ROYAL DSM N.V.
        • OVERVIEW
        • PRODUCT PORTFOLIO
        • SCOT ANALYSIS
        • STRATEGIC INITIATIVES
      • SANOFI
        • OVERVIEW
        • PRODUCT PORTFOLIO
        • SCOT ANALYSIS
        • STRATEGIC INITIATIVES
      • SHIRE
        • OVERVIEW
        • PRODUCT PORTFOLIO
        • SCOT ANALYSIS
        • STRATEGIC INITIATIVES
      • SUN PHARMACEUTICAL INDUSTRIES LTD
        • OVERVIEW
        • PRODUCTS PORTFOLIO
        • SCOT ANALYSIS
        • STRATEGIC INITIATIVES
      • ULTRAGENYX PHARMACEUTICAL INC.
        • OVERVIEW
        • PRODUCT PORTFOLIO
        • SCOT ANALYSIS
        • STRATEGIC INITIATIVES
      • ZERIA PHARMACEUTICAL
        • OVERVIEW
        • PRODUCT PORTFOLIO
        • SCOT ANALYSIS
        • STRATEGIC INITIATIVES

 

TABLE LIST

TABLE 1       ASIA PACIFIC HYPERPHOSPHATEMIA DRUG MARKET 2019-2027($ MILLION)

TABLE 2       IRON-BASED HYPERPHOSPHATEMIA DRUG APPROVAL STATUS 2014-2017

TABLE 3       WORLDWIDE POPULATION AGED 80 AND ABOVE 1950-2050 (MILLIONS)

TABLE 4       PHOSPHOROUS LEVELS IN SELECT FOODS

TABLE 5       ASIA PACIFIC HYPERPHOSPHATEMIA DRUGS MARKET BY FORMULATION 2019-2027($ MILLION)

TABLE 6       ASIA PACIFIC CALCIUM-BASED PHOSPHATE BINDERS 2019-2027($ MILLION)

TABLE 7       ASIA PACIFIC ALUMINUM-BASED PHOSPHATE BINDERS 2019-2027($ MILLION)

TABLE 8       ASIA PACIFIC MAGNESIUM-BASED PHOSPHATE BINDERS 2019-2027($ MILLION)

TABLE 9       ASIA PACIFIC IRON-BASED PHOSPHATE BINDERS 2019-2027($ MILLION)

TABLE 10     ASIA PACIFIC OTHER PHOSPHATE BINDERS 2019-2027($ MILLION)

TABLE 11     PIPELINE PORTFOLIO OF HYPERPHOSPHATEMIA DRUGS

TABLE 12     ASIA PACIFIC HYPERPHOSPHATEMIA DRUGS MARKET 2019-2027 ($ MILLION)

TABLE 13     ASIA-PACIFIC HYPERPHOSPHATEMIA DRUGS MARKET BY COUNTRY 2019-2027($ MILLION)

TABLE 14     PER CAPITA CONSUMPTION OF DAIRY PRODUCTS IN AUSTRALIA 2014 -2016

 

FIGURE LIST

FIGURE 1     RATE OF ADHERENCE TO PHOSPHATE BINDERS

FIGURE 2     DIAGNOSIS AND CLINICAL INDICATORS OF CHRONIC KIDNEY DISEASE

FIGURE 3     ASIA PACIFIC HYPERPHOSPHATEMIA DRUGS MARKET BY CALCIUM-BASED PHOSPHATE BINDERS 2019-2027($ MILLION)

FIGURE 4     ASIA PACIFIC HYPERPHOSPHATEMIA DRUGS MARKET BY ALUMINUM-BASED PHOSPHATE BINDERS 2019-2027($ MILLION)

FIGURE 5     ASIA PACIFIC HYPERPHOSPHATEMIA DRUGS MARKET BY MAGNESIUM-BASED PHOSPHATE BINDERS 2019-2027($ MILLION)

FIGURE 6     ASIA PACIFIC HYPERPHOSPHATEMIA DRUGS MARKET BY IRON-BASED PHOSPHATE BINDERS 2019-2027($ MILLION)

FIGURE 7     ASIA PACIFIC HYPERPHOSPHATEMIA DRUGS MARKET BY OTHER PHOSPHATE BINDERS 2019-2027($ MILLION)

FIGURE 8     PORTERS 5 FORCE MODEL OF HYPERPHOSPHATEMIA MARKET

FIGURE 9     ASIA-PACIFIC HYPERPHOSPHATEMIA DRUGS MARKET 2019-2027($ MILLION)

FIGURE 10   AGE WISE DISTRIBUTION OF ELDERLY POPULATION IN INDIA 2016

FIGURE 11   INDIA HYPERPHOSPHATEMIA DRUGS MARKET 2019-2027($ MILLION)

FIGURE 12   CHINA HYPERPHOSPHATEMIA DRUGS MARKET 2019-2027($ MILLION)

FIGURE 13   JAPAN HYPERPHOSPHATEMIA DRUGS MARKET 2019-2027($ MILLION)

FIGURE 14   NUMBER OF FRACTURES DUE TO OSTEOPOROSIS AND OSTEOPENIA ($ MILLION)

FIGURE 15   AUSTRALIA HYPERPHOSPHATEMIA DRUGS MARKET 2019-2027($ MILLION)

FIGURE 16   SOUTH KOREA HYPERPHOSPHATEMIA DRUGS MARKET 2019-2027($ MILLION)

FIGURE 17   ROAPAC HYPERPHOSPHATEMIA DRUGS MARKET 2019-2027($ MILLION)

FIGURE 18   MARKET SHARE ANALYSIS OF KEY PLAYERS 2017 (%)

  1. GEOGRAPHIC ANALYSIS
    • ASIA PACIFIC
      • INDIA
      • CHINA
      • JAPAN
      • AUSTRALIA
      • REST OF APAC
  1. MARKET SEGMENTATION
    • MARKET BY FORMULATION 2019-2027
      • CALCIUM-BASED PHOSPHATE BINDERS
      • ALUMINUM-BASED PHOSPHATE BINDERS
      • MAGNESIUM-BASED PHOSPHATE BINDERS
      • IRON-BASED PHOSPHATE BINDERS
      • OTHER PHOSPHATE BINDERS

To request a free sample copy of this report, please complete the form below :

We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.

Choose License Type

Buy Now